OTCMKTS:HSTC

HST Global Competitors

$0.24
+0.16 (+211.92 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.24
Now: $0.24
$0.24
50-Day Range
$0.07
MA: $0.08
$0.15
52-Week Range
$0.04
Now: $0.24
$0.40
Volume4,706 shs
Average Volume3,540 shs
Market Capitalization$1.24 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.52

Competitors

HST Global (OTCMKTS:HSTC) Vs. IPCIF, BCTXF, FWDG, ISCO, AMBS, and AKRXQ

Should you be buying HSTC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to HST Global, including Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), International Stem Cell (ISCO), Amarantus BioScience (AMBS), and Akorn (AKRXQ).

HST Global (OTCMKTS:HSTC) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares HST Global and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
Intellipharmaceutics International-232.11%N/A-81.71%

Earnings & Valuation

This table compares HST Global and Intellipharmaceutics International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
Intellipharmaceutics International$3.48 million1.38$-8,090,000.00N/AN/A

HST Global has higher earnings, but lower revenue than Intellipharmaceutics International.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and Intellipharmaceutics International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
Intellipharmaceutics International0000N/A

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Summary

Intellipharmaceutics International beats HST Global on 4 of the 6 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Institutional and Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 65.8% of HST Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares HST Global and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
BriaCell TherapeuticsN/AN/A-786.77%

Earnings & Valuation

This table compares HST Global and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and BriaCell Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
BriaCell Therapeutics0000N/A

Volatility & Risk

HST Global has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Summary

BriaCell Therapeutics beats HST Global on 4 of the 6 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares HST Global and FutureWorld's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
FutureWorldN/AN/AN/A

Earnings & Valuation

This table compares HST Global and FutureWorld's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
FutureWorldN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and FutureWorld, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
FutureWorld0000N/A

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, FutureWorld has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

FutureWorld beats HST Global on 3 of the 3 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and International Stem Cell, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
International Stem Cell0000N/A

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Earnings & Valuation

This table compares HST Global and International Stem Cell's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
International Stem Cell$9.47 million0.43$-4,260,000.00N/AN/A

HST Global has higher earnings, but lower revenue than International Stem Cell.

Profitability

This table compares HST Global and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
International Stem Cell-55.56%N/A-72.21%

Summary

International Stem Cell beats HST Global on 4 of the 6 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and HST Global (OTCMKTS:HSTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Amarantus BioScience and HST Global, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarantus BioScience0000N/A
HST Global0000N/A

Valuation and Earnings

This table compares Amarantus BioScience and HST Global's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarantus BioScienceN/AN/AN/AN/AN/A
HST GlobalN/AN/A$430,000.00N/AN/A

Risk and Volatility

Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, HST Global has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by company insiders. Comparatively, 65.8% of HST Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Amarantus BioScience and HST Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarantus BioScienceN/AN/AN/A
HST GlobalN/A-1,715.09%-13,300.29%

Summary

Amarantus BioScience beats HST Global on 4 of the 5 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for HST Global and Akorn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HST Global0000N/A
Akorn0000N/A

Valuation and Earnings

This table compares HST Global and Akorn's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HST GlobalN/AN/A$430,000.00N/AN/A
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

HST Global has higher earnings, but lower revenue than Akorn.

Risk and Volatility

HST Global has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 65.8% of HST Global shares are owned by insiders. Comparatively, 3.9% of Akorn shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares HST Global and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HST GlobalN/A-1,715.09%-13,300.29%
Akorn-54.01%-5.13%-0.49%

Summary

Akorn beats HST Global on 5 of the 8 factors compared between the two stocks.


HST Global Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20+0.0%$4.81 million$3.48 million-1.69Gap Down
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01News Coverage
FutureWorld logo
FWDG
FutureWorld
0.5$0.00+0.0%$4.56 millionN/A0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.54+11.1%$4.07 million$9.47 million0.00High Trading Volume
Gap Down
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01+0.0%$3.87 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
AKRXQ
Akorn
0.1$0.03+0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01+0.0%$3.50 millionN/A0.00Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.09+0.0%$3.50 million$3.65 million0.00News Coverage
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14+7.3%$2.88 millionN/A0.00Gap Up
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04+0.0%$2.82 millionN/A-0.09
VVUSQ
VIVUS
0.6$0.12+0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48+6.2%$2.02 millionN/A0.00
NSPX
Inspyr Therapeutics
0.5$0.01+0.0%$1.97 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01+0.0%$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04+0.0%$1.78 million$530,000.000.00Gap Up
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48+6.2%$1.70 millionN/A0.00
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.01+0.0%$1.65 million$20,000.00-0.74Gap Down
Cardax logo
CDXI
Cardax
0.0$2.00+0.0%$1.59 million$710,000.000.00News Coverage
MLNTQ
Melinta Therapeutics
0.2$0.11+0.0%$1.51 million$96.43 million0.00
WWHC
W World
0.8$4.50+35.3%$1.33 millionN/A0.00Increase in Short Interest
Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+0.0%$1.29 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22+9.3%$1.14 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+0.0%$1.12 millionN/A-0.57Upcoming Earnings
AOXG
Aoxing Pharmaceutical
0.5$0.01+0.0%$991,000.00N/A0.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+0.0%$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+0.0%$970,000.00N/A0.00Increase in Short Interest
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+0.0%$958,000.00N/A0.00Increase in Short Interest
Gap Up
SPHS
Sophiris Bio
0.1$0.03+39.1%$910,000.00N/A0.00Increase in Short Interest
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08+0.0%$872,000.00$250,000.000.00
PXYN
Praxsyn
0.6$0.00+0.0%$848,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+0.0%$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02+0.0%$547,000.00N/A0.00Gap Up
TRPXD
Therapix Biosciences
0.0$9.25+2.7%$462,000.00N/A0.00High Trading Volume
Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.15+46.4%$399,000.00N/A0.00News Coverage
SKVI
Skinvisible
0.7$0.08+83.3%$376,000.00$40,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+0.0%$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+0.0%$244,000.00N/A0.00
WDBG
Woodbrook Group
0.0$1.60+0.0%$224,000.00N/A0.00
PZRXQ
PhaseRx
0.2$0.02+0.0%$185,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.08+24.2%$151,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01+69.0%$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00+0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01+0.0%$7,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.04+22.7%$0.00N/A0.00
Affymax logo
AFFY
Affymax
0.6$0.08+12.5%$0.00N/A0.00Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.